We are live on
!
Find out more
PJC
Phillip James Consulting Portfolio holdings
AUM
$150M
This Fund
S&P 500
This Quarter
Est. Return
+3.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.67M
AUM Growth
–
Cap. Flow
+$5.75M
Cap. Flow
% of AUM
101.49%
Top 10 Holdings %
Top 10 Hldgs %
63.11%
Holding
95
New
95
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.65M |
| 2 |
Microsoft
MSFT
|
+$538K |
| 3 |
UnitedHealth
UNH
|
+$328K |
| 4 |
Best Buy
BBY
|
+$271K |
| 5 |
Amazon
AMZN
|
+$261K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.79% |
| 2 | Healthcare | 16.01% |
| 3 | Consumer Discretionary | 15.81% |
| 4 | Financials | 10.36% |
| 5 | Industrials | 8.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ameriprise Financial
AMP
$49.1B
| $49K | 0.86% |
+100
| New | +$47.5K |
|
27
Dover
DOV
$27.2B
| $49K | 0.86% |
+245
| New | +$44.6K |
|
28
Citigroup
C
$223B
| $47K | 0.83% |
+413
| New | +$42.9K |
|
29
KLA
KLAC
$240B
| $46K | 0.81% |
+310
| New | +$36.4K |
|
30
Thermo Fisher Scientific
TMO
$233B
| $46K | 0.81% |
+75
| New | +$42.4K |
|
31
Coca-Cola
KO
$383B
| $43K | 0.76% |
+600
| New | +$41.8K |
|
32
Motorola Solutions
MSI
$80.5B
| $43K | 0.76% |
+111
| New | +$44.6K |
|
33
Northrop Grumman
NOC
$77.4B
| $39K | 0.69% |
+60
| New | +$34.8K |
|
34
AbbVie
ABBV
$456B
| $36K | 0.64% |
+168
| New | +$38.3K |
|
35
Synopsys
SNPS
$89B
| $36K | 0.64% |
+71
| New | +$31.5K |
|
36
State Street
STT
$53.1B
| $30K | 0.53% |
+240
| New | +$28.7K |
|
37
Boeing
BA
$166B
| $28K | 0.49% |
+112
| New | +$23K |
|
38
Starbucks
SBUX
$122B
| $28K | 0.49% |
+296
| New | +$25K |
|
39
Chevron
CVX
$392B
| $26K | 0.46% |
+157
| New | +$23.9K |
|
40
Home Depot
HD
$328B
| $23K | 0.41% |
+62
| New | +$22.7K |
|
41
Prudential Financial
PRU
$41.5B
| $23K | 0.41% |
+213
| New | +$22.8K |
|
42
Blackstone
BX
$108B
| $22K | 0.39% |
+143
| New | +$21.7K |
|
43
Abbott
ABT
$193B
| $20K | 0.35% |
+168
| New | +$21.4K |
|
44
Goldman Sachs
GS
$303B
| $20K | 0.35% |
+21
| New | +$17.1K |
|
45
HCA Healthcare
HCA
$90.8B
| $17K | 0.3% |
+37
| New | +$17.2K |
|
46
Morgan Stanley
MS
$337B
| $16K | 0.28% |
+90
| New | +$15K |
|
47
Cardinal Health
CAH
$54.7B
| $15K | 0.26% |
+69
| New | +$13K |
|
48
Agilent Technologies
A
$44.5B
| $14K | 0.25% |
+100
| New | +$14.4K |
|
49
Bristol-Myers Squibb
BMY
$137B
| $14K | 0.25% |
+262
| New | +$12.6K |
|
50
Pfizer
PFE
$160B
| $14K | 0.25% |
+547
| New | +$13.8K |
|
Similar funds
AIM
SHFC
BCCM
PF
CFG
LC
EC
SSCM
Phillip James Consulting's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Phillip James Consulting, which disclosed 95 positions worth $5.67M. Its ten largest holdings account for 63% of the portfolio.
Its largest position is Apple: 6,134 shares worth $1.51M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, followed by Healthcare and Consumer Discretionary.
- Phillip James Consulting's largest Q4 2025 buy was Apple: 6,134 shares worth $1.51M.
- Phillip James Consulting's ten largest holdings make up 63% of its $5.67M portfolio in Q4 2025.
- Phillip James Consulting disclosed 95 positions in Q4 2025, its first 13F filing on record.
Based on Phillip James Consulting's 13F filing for Q4 2025, filed 23 Feb 2026.